PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 3, 2026International Journal of Rheumatic Diseases0 citationsOpen Access

Certolizumab Pegol Reduced Anterior Uveitis Flares Compared With Standard Non‐Biologic Treatment: Results From an Overlap Weighting Analysis in High‐Risk Patients With Axial Spondyloarthritis

View Full Paper
NHNigil HaroonZBZeynep BaskurtTCTina Hiu Tung Chim

Key Points

  • The aim is to evaluate the effectiveness of certolizumab pegol in reducing anterior uveitis flares compared to standard non-biologic treatment in high-risk patients with axial spondyloarthritis.
  • Conducted an overlap weighting analysis
  • Compared certolizumab pegol with standard non-biologic treatment
  • Focused on high-risk patients with axial spondyloarthritis
  • Certolizumab pegol significantly reduced the frequency of anterior uveitis flares
  • Improved clinical outcomes compared to standard treatment
  • Supported previous findings from the C-VIEW study

Abstract

This study supports the findings of C-VIEW and demonstrates the benefit of CZP over standard non-biologic treatment as a promising therapeutic option in reducing AAU flares among high-risk patients with axSpA.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Haroon et al. (2026) studied this question.

synapsesocial.com/papers/69cf5ecb5a333a821460d78ahttps://doi.org/10.1111/1756-185x.70621
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1AB0913 EFFICACY OF CERTOLIZUMAB PEGOL IN PREVENTING ANTERIOR UVEITIS FLARES COMPARED WITH STANDARD NON-BIOLOGIC TREATMENT: A MATCHED CONTROL STUDY IN HIGH-RISK PATIENTS WITH AXIAL SPONDYLOARTHRITIS2024
  2. 2Certolizumab pegol in the treatment of axial spondyloarthritis2024
  3. 3Exploratory analysis of the potential disconnect between objective inflammatory response and clinical response following certolizumab pegol treatment in patients with active axial spondyloarthritis2024 · 2 citations
  4. 4OA11 Maintained improvement in patient reported outcomes in early axial spondyloarthritis following certolizumab pegol dose reduction2024
  5. 5Safety and effectiveness of certolizumab pegol in Japanese patients with rheumatoid arthritis: Up to 3-year results from a postmarketing surveillance study2024 · 2 citations